Trial Profile
Enzalutamide and Metformin Combination Therapy to Overcome Autophagy Resistance in Castration Resistant Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Sep 2023
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Metformin (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 30 Aug 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 30 Aug 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Apr 2024.
- 04 Oct 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.